Table 3 Characteristics of nr-axSpA patients at initiation of first TNFi treatment with available follow-up visit at 1 year (patients with co-morbid fibromyalgia excluded)
Parameter | A. Nr-axSpA patients with available follow-up visit at 1 year | B. Nr-axSpA patients still on TNFi treatment at 1 year | ||||||
|---|---|---|---|---|---|---|---|---|
N, 120 | Men, N = 58 | Women, N = 62 | p | N, 83 | Men, N = 45 | Women, N = 38 | p | |
Age, years | 120 | 36.0 (10.8) | 38.6 (11.4) | 0.25 | 83 | 34.6 (10.3) | 39.2 (13.4) | 0.16 |
Age at onset, years | 120 | 27.7 (8.4) | 27.9 (8.2) | 0.78 | 83 | 27.4 (8.0) | 27.4 (7.5) | 0.89 |
Symptom duration, years | 120 | 8.3 (9.5) | 10.7 (11.3) | 0.27 | 83 | 7.2 (7.8) | 11.7 (12.2) | 0.12 |
Diagnostic delay, years | 120 | 4.7 (8.6) | 7.3 (10.1) | 0.03 | 83 | 3.0 (5.3) | 7.4 (10.3) | 0.02 |
HLA-B27 positive, % | 110 | 79.6 | 73.2 | 0.50 | 78 | 83.3 | 77.8 | 0.58 |
Prior sacroiliitis on MRI, % | 112 | 67.9 | 67.8 | 1.00 | 77 | 66.7 | 65.7 | 1.00 |
BASDAI | 108 | 5.4 (2.0) | 6.1 (1.6) | 0.05 | 74 | 5.2 (2.0) | 5.9 (1.6) | 0.09 |
Physician Global Assessment | 115 | 5.1 (1.9) | 4.8 (1.7) | 0.54 | 81 | 5.3 (2.0) | 4.7 (1.8) | 0.28 |
Patient Global Assessment | 109 | 6.6 (2.2) | 6.7 (1.9) | 1.00 | 75 | 6.5 (2.2) | 6.4 (2.0) | 0.89 |
ASDAS | 100 | 3.4 (0.9) | 3.4 (0.7) | 0.63 | 69 | 3.4 (0.9) | 3.4 (0.6) | 0.90 |
ASDAS > 2.1, % | 100 | 88.9 | 94.5 | 0.46 | 69 | 91.7 | 97.0 | 0.62 |
CRP (mg/l), median (IQR) | 111 | 7.0 (2.0; 15.0) | 7.0 (3.0; 10.0) | 0.63 | 77 | 7.3 (3.0; 19.5) | 7.0 (3.5; 10.5) | 0.37 |
Elevated CRP, % | 111 | 47.2 | 43.1 | 0.71 | 77 | 54.8 | 42.9 | 0.36 |
BASFI | 109 | 3.7 (2.4) | 3.5 (2.4) | 0.61 | 75 | 3.5 (2.4) | 3.2 (2.3) | 0.53 |
BASMI | 102 | 1.2 (1.1) | 1.4 (1.2) | 0.37 | 70 | 1.1 (1.1) | 1.2 (1.3) | 0.88 |
EQ-5D | 103 | 53.7 (22.8) | 57.6 (17.8) | 0.52 | 70 | 55.6 (21.7) | 59.2 (15.7) | 0.65 |
Current periph. arthritis,% | 116 | 47.4 | 47,5 | 1.00 | 82 | 46.7 | 54.0 | 0.66 |
Number of swollen joints | 113 | 0.7 (1.2) | 1.2 (2.6) | 0.83 | 80 | 0.8 (1.3) | 1.5 (2.9) | 0.52 |
Current enthesitis, % | 115 | 80.7 | 86.2 | 0.46 | 82 | 80.0 | 86.5 | 0.56 |
Modified MASES | 114 | 2.4 (2.6) | 3.7 (3.2) | 0.02 | 81 | 2.1 (2.2) | 3.4 (2.7) | 0.03 |
Dactylitis ever, % | 118 | 16.1 | 19.4 | 0.81 | 82 | 11.4 | 21.1 | 0.36 |
csDMARDs ever, % | 120 | 31.0 | 40.3 | 0.34 | 83 | 26.7 | 36.8 | 0.35 |
Taking NSAIDs, % | 109 | 94.1 | 86.2 | 0.21 | 76 | 100.0 | 85.7 | 0.02 |
Current smoking, % | 102 | 28.9 | 15.8 | 0.15 | 68 | 26.5 | 8.8 | 0.11 |
Body mass index | 120 | 25.9 (4.2) | 24.0 (4.4) | 0.002 | 83 | 25.6 (4.2) | 23.6 (4.7) | 0.004 |
Type of TNFi, % | 120 | 0.69 | 83 | 0.38 | ||||
• Adalimumab | 34.5 | 43.5 | 35.6 | 50.0 | ||||
• Certolizumab | 1.7 | 0.0 | 2.2 | 0.0 | ||||
• Etanercept | 19.0 | 16.1 | 20.0 | 10.5 | ||||
• Golimumab | 22.4 | 24.2 | 20.0 | 26.3 | ||||
• Infliximab | 22.4 | 16.1 | 22.2 | 13.2 | ||||